Trials / Completed
CompletedNCT00002274
A Study of ddI in Patients With AIDS Who Become Sicker While Taking Zidovudine
An Open Label Study Regimen of Videx (2',3'-Dideoxyinosine, ddI) in Patients With Acquired Immunodeficiency Syndrome (AIDS) Exhibiting Significant Deterioration While Taking Zidovudine (Retrovir)
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this open-label study regimen is to make didanosine (ddI) available to patients with AIDS who are clinically deteriorating on zidovudine (AZT) and cannot enter the Phase II ddI programs due to protocol exclusion or geographic location.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Didanosine |
Timeline
- First posted
- 2001-08-31
- Last updated
- 2007-10-02
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00002274. Inclusion in this directory is not an endorsement.